People · Operator
Named in public records as an officer, director or promoter · active 2023–2023 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| MAPS Public Benefit Corp | — | Pharmaceuticals | Series D+ | $215.1M | $2.9B | 2023 |
Andrew Septimus at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Andrew Septimus on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Jason Pyle | 1 | 3 |
| ARMAN NADERSHAHI | 1 | 3 |
| Amy Emerson | 1 | 1 |
| Berra Yazar-Klosinski | 1 | 1 |
| Michael Mullette | 1 | 1 |
| Blair Clark-Schoeb | 1 | 1 |
| Dawn McCollough | 1 | 1 |
| Suprotik Basu | 1 | 1 |
| Gisselle Acevedo | 1 | 1 |
| Daniel Grossman | 1 | 1 |
| Richard Doblin | 1 | 1 |
| James Acer | 1 | 1 |
| Jeffery George | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.